Interim analysis: Open-label extension study of leniolisib for patients with APDS
Journal of Allergy and Clinical Immunology · 2024-01 · 153 (1) · 265-274.e9
DOI: 10.1016/j.jaci.2023.09.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024-01. Verfasst von V Koneti Rao und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address: korao@niaid.nih.gov. Hauptthemen laut MEDLINE: Immunologic Deficiency Syndromes, Lymphadenopathy. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS; or p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency) is an inborn error of immunity caused by PI3Kδ hyperactivity. Resultant immune deficiency and dysregulation lead to recurrent sinopulmonary infections, herpes viremia, autoimmunity, and lymphoproliferation. OBJECTIVE: Leniolisib, a selective PI3Kδ inhibitor, demonstrated favorable impact on immune cell subsets and lymphoproliferation over placebo in patients with APDS over 12 weeks. Here, we report results from an interim analysis of an ongoing open-label, single-arm extension study. METHODS: Patients with APDS aged 12 years or older who completed NCT02435173 or had previous exposure to PI3Kδ inhibitors were eligible. The primary end point was safety, assessed via investigator-reported adverse events (AEs) and clinical/laboratory evaluations. Secondary and exploratory end points included health-related quality of life, inflammatory markers, frequency of infections, and lymphoproliferation. RESULTS: Between September 2016 and August 2021, 37 patients (median age, 20 years; 42.3% female) were enrolled. Of these 37 patients, 26, 9, and 2 patients had previously received leniolisib, placebo, or other PI3Kδ inhibitors, respectively. At the data cutoff date (December 13, 2021), median leniolisib exposure was 102 weeks. Overall, 32 patients (87%) experienced an AE. Most AEs were grades 1 to 3; none were grade 4. One patient with severe baseline comorbidities experienced a grade 5 AE, determined as unrelated to leniolisib treatment. While on leniolisib, patients had reduced annualized infection rates (P = .004), and reductions in immunoglobulin replacement therapy occurred in 10 of 27 patients. Other observations include reduced lymphadenopathy and splenomegaly, improved cytopenias, and normalized lymphocyte subsets. CONCLUSIONS: Leniolisib was well tolerated and maintained durable outcomes with up to 5 years of exposure in 37 patients with APDS. CLINICALTRIALS: gov identifier: NCT02859727.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address: korao@niaid.nih.gov.
- Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Bethesda, Md.
- Department of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
- Pediatrics Clinic, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.
- Department of Pediatric Immunology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
- Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Förderung
- Intramural NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Rao, V. K., Kulm, E., Šedivá, A., Plebani, A., Schuetz, C., Shcherbina, A., Dalm, V. A., Trizzino, A., Zharankova, Y., Webster, S., Orpia, A., Körholz, J., Lougaris, V., Rodina, Y., Radford, K., Bradt, J., Relan, A., Holland, S. M., Lenardo, M. J., & Uzel, G. (2024). Interim analysis: Open-label extension study of leniolisib for patients with APDS. Journal of Allergy and Clinical Immunology, 153(1), 265-274.e9. https://doi.org/10.1016/j.jaci.2023.09.032
Vancouver
Rao VK, Kulm E, Šedivá A, Plebani A, Schuetz C, Shcherbina A, et al. Interim analysis: Open-label extension study of leniolisib for patients with APDS. Journal of Allergy and Clinical Immunology. 2024;153(1):265-274.e9. doi:10.1016/j.jaci.2023.09.032
BibTeX
@article{Rao2024,
author = {Rao, V Koneti and Kulm, Elaine and Šedivá, Anna and Plebani, Alessandro and Schuetz, Catharina and Shcherbina, Anna and Dalm, Virgil A and Trizzino, Antonino and Zharankova, Yulia and Webster, Sharon and Orpia, Alanvin and Körholz, Julia and Lougaris, Vassilios and Rodina, Yulia and Radford, Kath and Bradt, Jason and Relan, Anurag and Holland, Steven M and Lenardo, Michael J and Uzel, Gulbu},
title = {Interim analysis: Open-label extension study of leniolisib for patients with APDS},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
volume = {153},
number = {1},
pages = {265--274.e9},
doi = {10.1016/j.jaci.2023.09.032}
}
EUVIMED